Skip to Content (custom)

      Beyond Itch Control: Why Skin Barrier Repair Matters in the Management of Canine and Feline Atopic Dermatitis

      A Modern, Multimodal Approach to Long-Term Skin Health
      Atopic dermatitis (AD) is one of the most common chronic dermatologic diseases affecting dogs and, to a lesser extent, cats. While pruritus is often the most noticeable clinical sign, AD is a complex condition involving both immune dysregulation and impaired skin barrier function.
      Advances in veterinary medicine—including Janus kinase (JAK) inhibitors and other targeted therapies—have significantly improved itch control and patient comfort. However, systemic therapies do not restore the skin's protective barrier or address changes occurring at the skin surface.
      For this reason, topical therapy remains an important component of multimodal dermatologic care. In addition to cleansing the skin and managing microbial overgrowth, appropriately formulated topical products help support epidermal barrier function and long-term skin health.
      Pivetal® Suffusion™ K was developed with this comprehensive approach in mind by combining proven antimicrobial ingredients with a proprietary Skin-Identical Lipid Complex to support healthy skin barrier function.

      Atopic Dermatitis Is More Than an Itch Disorder
      Healthy skin functions as the body's first line of defense by:
      • Helping retain moisture
      • Limiting penetration of allergens and irritants
      • Supporting a balanced skin microbiome
      • Protecting against opportunistic microorganisms
      In patients with atopic dermatitis, abnormalities in epidermal lipids—particularly ceramides—can compromise this protective barrier. The result is increased transepidermal water loss (TEWL), greater allergen penetration, microbial imbalance, and recurring inflammation.
      When the barrier becomes compromised, a self-perpetuating cycle of itch, scratching, inflammation, and secondary bacterial or yeast overgrowth can develop. Successful long-term management addresses both inflammation and restoration of the skin barrier.

      Why Topical Therapy Matters
      While systemic medications effectively target itch and inflammation, they do not physically repair the epidermal barrier or cleanse the skin surface.
      Topical therapy complements systemic treatment by helping to:
      • Remove allergens and debris
      • Cleanse areas affected by bacterial and yeast overgrowth
      • Support hydration
      • Maintain normal barrier function
      • Condition the skin and coat
      • Provide ongoing support between flare-ups
      This complementary role is why topical therapy continues to be recommended in veterinary dermatology guidelines as part of comprehensive patient management.

      Barrier-Supportive Ingredients
      Pivetal® Suffusion™ K incorporates a proprietary Skin-Identical Lipid Complex designed to support healthy epidermal function.
      Ingredient Function
      Ceramides (NP, AP & EOP) Help replenish the lipid barrier and reduce transepidermal water loss.
      Phytosphingosine Supports ceramide metabolism and healthy skin structure.
      Cholesterol & Free Fatty Acids Essential components of a healthy epidermal lipid matrix.
      Avenanthramides Naturally derived oat compounds that help condition and soothe irritated skin while providing antioxidant support.
      Together, these ingredients help support normal barrier function while promoting healthy skin hydration and integrity.

      Managing Microbial Imbalance
      Compromised skin barriers frequently allow bacterial and yeast populations to proliferate more readily.
      Pivetal® Suffusion™ K combines two well-established topical ingredients:
      • Chlorhexidine – A broad-spectrum antiseptic commonly used to cleanse the skin and help manage bacterial populations.
      • Ketoconazole – A topical antifungal ingredient used in products intended for skin conditions responsive to fungal organisms.
      Together, these ingredients provide complementary antimicrobial activity while barrier-supportive lipids help maintain healthy skin.

      Complementing Systemic Therapy
      Modern systemic therapies—including JAK inhibitors—provide rapid relief from itch and inflammation. However, they do not restore depleted epidermal lipids, repair the skin barrier, remove allergens from the skin surface, or cleanse areas affected by microbial overgrowth.
      By combining systemic therapy with barrier-supportive topical care, clinicians can address both the clinical signs of atopic dermatitis and the skin environment that contributes to recurring flare-ups.

      Why Choose Pivetal® Suffusion™ K?
      Pivetal® Suffusion™ K was developed to support comprehensive dermatologic care by combining:
      • Broad-spectrum topical cleansing
      • Antifungal support
      • Proprietary Skin-Identical Lipid Complex
      • Barrier-supportive ingredients
      • Skin-conditioning technology
      Rather than focusing solely on microbial management, Suffusion™ K helps support both skin hygiene and epidermal barrier health—two essential components of long-term dermatologic care.

      Clinical Applications
      Pivetal® Suffusion™ K may be incorporated into individualized dermatologic protocols for:
      • Initial management of flare-ups alongside systemic therapy
      • Routine maintenance following flare resolution
      • Seasonal allergy management
      • Patients experiencing recurrent bacterial or yeast overgrowth
      • Long-term skin conditioning as part of an individualized care plan
      Treatment recommendations should always be tailored to the patient's underlying condition and clinical presentation.

      Looking Beyond Clinical Signs
      Successful management of atopic dermatitis extends beyond controlling itch.
      Supporting skin barrier integrity alongside microbial management helps promote healthier skin over time and complements the benefits of systemic therapies.
      Pivetal® Suffusion™ K reflects today's multimodal approach to veterinary dermatology by combining proven antimicrobial ingredients with a proprietary Skin-Identical Lipid Complex to help veterinarians support healthy skin barrier function throughout every stage of patient care.
       
      Share

      Related blogs

      July 06, 2026
      Navigating Vaccine Hesitancy: A Path to Enhanced Preventive Care
      Vaccine hesitancy in veterinary medicine poses a substantial challenge to optimal patient care. It undermines effective protection against vaccine-preventable diseases and, in certain instances, public health. As veterinary professionals, understanding this landscape is crucial for effective client engagement in order to protect dogs and cats against vaccine preventable diseases.
      September 24, 2025
      4 Stages for Feline Hypertrophic Cardiomyopathy (HCM) – and 2 New Treatment Options

      HCM, otherwise known as Hypertrophic Cardiomyopathy, is the most common cardiac disease in cats, affecting nearly 14% of the population. 

      Though prevalence is high, diagnosis is not so easy, which is why awareness is so important. 

      Learn more about the 4 stages of Feline Hypertrophic Cardiomyopathy as well as what treatment options are available to those affected.